Patients with NSCLC expressing certain activating EGFR mutations are much more likely to respond to EGFR inhibitors (17), and thus such tumors appear to be particularly addicted to EGFR signaling for survival. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.